Experimental drug aims to wake up immune system against tough leukemia
NCT ID NCT06626633
First seen Oct 31, 2025 · Last updated Jun 18, 2026 · Updated 30 times
Summary
This early-phase trial tests a new drug called CRD3874-SI that activates the STING protein to help the immune system fight cancer cells. It is for adults with acute myeloid leukemia that has come back or not responded to standard treatments. The main goals are to check safety and find the best dose, with only 6 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Maryland, Baltimore
Baltimore, Maryland, 21201, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.